DANAHER CORP

Danaher’s Form 3 filings reveal how senior execs hold stock, deferred‑comp shares, and options, aligning incentives with shareholder value and compliance.

Danaher crowns Julie Sawyer Montgomery as president‑CEO, driving innovation, diagnostics, and operational excellence to strengthen its life‑sciences leadership and patient impact.

Discover how Danaher Corp’s precision diagnostics and strategic M&A fuel growth, cutting costs & improving patient outcomes—insights for investors & clinicians.

Explore Danaher’s decade‑long surge: 300%+ returns, disciplined capital, and future‑ready diagnostics & AI growth—why investors keep buying.

Danaher’s latest quarter shows 8% revenue growth, 32% EBITDA margin, and a new quarterly dividend—highlighting its integrated diagnostics ecosystem and shareholder‑value focus.

Danaher’s new $0.40 dividend shows a firm balancing steady cash flow with pipeline growth, patent‑cliff risk mitigation, and strategic M&A to drive long‑term value.

Danaher’s CEO sells shares, yet keeps a 38k‑share trust stake – a routine, transparent move that keeps governance stable and investors reassured.

Danaher Corp’s insider sale & eyeQ valuation show a 12% fair‑value gap—underscoring long‑term science‑driven growth & macro resilience.

Danaher’s Rule 144 filing shows why its high‑precision medical devices keep hospitals ahead of reimbursement shifts, capital constraints, and workflow hurdles—delivering measurable cost savings and better patient outcomes.

Healthcare gains powered by Moderna, Merck, Lilly and others lift the S&P 500, showing how drug approvals, market‑access deals and M&A fuel sector resilience.